BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company focused on developing novel antibacterial products for multi-drug resistant (MDR) infections, announced today that all proposals by the Board of Directors were approved by shareholders at its Annual General Meeting.
Dr. Seng Chin Mah, Chairman of the Board, expressed gratitude for shareholder support, stating, 'Having achieved FPFV for the global BV100 Phase 3 trial, we are completely focused on eventually bringing this therapeutic option to patients in dire need. Our teams are equally determined to progress alpibectir and our preclinical pipeline with our partners.'
Key approvals included the 2025 annual report, financial statements, and the re-election of Seng Chin Mah as Chairman, along with board members David Hunstad, Marc Gitzinger, Marina von Schonau, and Ulrik Schulze. Ms. Simona Skerjanec was elected as a new member of the Board of Directors, replacing Dr. William Jenkins, whom the company thanked for his contributions.
Shareholders also approved compensation packages for the Board through the 2027 AGM and for the Executive Committee for fiscal year 2027. The minutes and related documents, including the Annual Report, are available on the company’s website, along with AGM details.
BioVersys is advancing BV100, a Phase 3 candidate for Acinetobacter baumannii infections, and alpibectir, a tuberculosis treatment in Phase 2 with GlaxoSmithKline and the University of Lille. The company’s platforms, TRIC and Ansamycin Chemistry, target resistance mechanisms and virulence production in MDR bacteria.
The approval of all proposals signals strong shareholder confidence in BioVersys’ strategy, particularly as it progresses pivotal trials for urgently needed antibiotics. With multidrug-resistant infections posing a growing global health threat, the company’s pipeline addresses high unmet medical needs in hospital-acquired infections and tuberculosis.
